Cargando…
CEPICS: A Comparison and Evaluation Platform for Integration Methods in Cancer Subtyping
Cancer subtypes can improve our understanding of cancer, and suggest more precise treatment for patients. Multi-omics molecular data can characterize cancers at different levels. Up to now, many computational methods that integrate multi-omics data for cancer subtyping have been proposed. However, t...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792302/ https://www.ncbi.nlm.nih.gov/pubmed/31649733 http://dx.doi.org/10.3389/fgene.2019.00966 |
_version_ | 1783459120841490432 |
---|---|
author | Duan, Ran Gao, Lin Xu, Han Song, Kuo Hu, Yuxuan Wang, Hongda Dong, Yongqiang Zhang, Chenxing Jia, Songwei |
author_facet | Duan, Ran Gao, Lin Xu, Han Song, Kuo Hu, Yuxuan Wang, Hongda Dong, Yongqiang Zhang, Chenxing Jia, Songwei |
author_sort | Duan, Ran |
collection | PubMed |
description | Cancer subtypes can improve our understanding of cancer, and suggest more precise treatment for patients. Multi-omics molecular data can characterize cancers at different levels. Up to now, many computational methods that integrate multi-omics data for cancer subtyping have been proposed. However, there are no consistent criteria to evaluate the integration methods due to the lack of gold standards (e.g., the number of subtypes in a specific cancer). Since comprehensive evaluation and comparison between different methods serves as a useful tool or guideline for users to select an optimal method for their own purpose, we develop a scalable platform, CEPICS, for comprehensively evaluating and comparing multi-omics data integration methods in cancer subtyping. Given a user-specified maximum number of subtypes, k-max, CEPICS provides (1) cancer subtyping results using up to five built-in state-of-the-art integration methods under the number of subtypes from two to k-max, (2) a report including the evaluation of each user-selected method and comparisons across them using clustering performance metrics and clinical survival analysis, and (3) an overall analysis of subtyping results by different methods representing a robust cancer subtype prediction for samples. Furthermore, users can upload subtyping results of their own methods to compare with the built-in methods. CEPICS is implemented as an R package and is freely available at https://github.com/GaoLabXDU/CEPICS. |
format | Online Article Text |
id | pubmed-6792302 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-67923022019-10-24 CEPICS: A Comparison and Evaluation Platform for Integration Methods in Cancer Subtyping Duan, Ran Gao, Lin Xu, Han Song, Kuo Hu, Yuxuan Wang, Hongda Dong, Yongqiang Zhang, Chenxing Jia, Songwei Front Genet Genetics Cancer subtypes can improve our understanding of cancer, and suggest more precise treatment for patients. Multi-omics molecular data can characterize cancers at different levels. Up to now, many computational methods that integrate multi-omics data for cancer subtyping have been proposed. However, there are no consistent criteria to evaluate the integration methods due to the lack of gold standards (e.g., the number of subtypes in a specific cancer). Since comprehensive evaluation and comparison between different methods serves as a useful tool or guideline for users to select an optimal method for their own purpose, we develop a scalable platform, CEPICS, for comprehensively evaluating and comparing multi-omics data integration methods in cancer subtyping. Given a user-specified maximum number of subtypes, k-max, CEPICS provides (1) cancer subtyping results using up to five built-in state-of-the-art integration methods under the number of subtypes from two to k-max, (2) a report including the evaluation of each user-selected method and comparisons across them using clustering performance metrics and clinical survival analysis, and (3) an overall analysis of subtyping results by different methods representing a robust cancer subtype prediction for samples. Furthermore, users can upload subtyping results of their own methods to compare with the built-in methods. CEPICS is implemented as an R package and is freely available at https://github.com/GaoLabXDU/CEPICS. Frontiers Media S.A. 2019-10-08 /pmc/articles/PMC6792302/ /pubmed/31649733 http://dx.doi.org/10.3389/fgene.2019.00966 Text en Copyright © 2019 Duan, Gao, Xu, Song, Hu, Wang, Dong, Zhang and Jia http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Genetics Duan, Ran Gao, Lin Xu, Han Song, Kuo Hu, Yuxuan Wang, Hongda Dong, Yongqiang Zhang, Chenxing Jia, Songwei CEPICS: A Comparison and Evaluation Platform for Integration Methods in Cancer Subtyping |
title | CEPICS: A Comparison and Evaluation Platform for Integration Methods in Cancer Subtyping |
title_full | CEPICS: A Comparison and Evaluation Platform for Integration Methods in Cancer Subtyping |
title_fullStr | CEPICS: A Comparison and Evaluation Platform for Integration Methods in Cancer Subtyping |
title_full_unstemmed | CEPICS: A Comparison and Evaluation Platform for Integration Methods in Cancer Subtyping |
title_short | CEPICS: A Comparison and Evaluation Platform for Integration Methods in Cancer Subtyping |
title_sort | cepics: a comparison and evaluation platform for integration methods in cancer subtyping |
topic | Genetics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792302/ https://www.ncbi.nlm.nih.gov/pubmed/31649733 http://dx.doi.org/10.3389/fgene.2019.00966 |
work_keys_str_mv | AT duanran cepicsacomparisonandevaluationplatformforintegrationmethodsincancersubtyping AT gaolin cepicsacomparisonandevaluationplatformforintegrationmethodsincancersubtyping AT xuhan cepicsacomparisonandevaluationplatformforintegrationmethodsincancersubtyping AT songkuo cepicsacomparisonandevaluationplatformforintegrationmethodsincancersubtyping AT huyuxuan cepicsacomparisonandevaluationplatformforintegrationmethodsincancersubtyping AT wanghongda cepicsacomparisonandevaluationplatformforintegrationmethodsincancersubtyping AT dongyongqiang cepicsacomparisonandevaluationplatformforintegrationmethodsincancersubtyping AT zhangchenxing cepicsacomparisonandevaluationplatformforintegrationmethodsincancersubtyping AT jiasongwei cepicsacomparisonandevaluationplatformforintegrationmethodsincancersubtyping |